Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,228,959
  • Shares Outstanding, K 309,587
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,650 K
  • EBIT $ -144 M
  • EBITDA $ -150 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.14

Options Overview Details

View History
  • Implied Volatility 121.12% (-35.53%)
  • Historical Volatility 51.28%
  • IV Percentile 13%
  • IV Rank 2.50%
  • IV High 1,077.61% on 04/10/25
  • IV Low 96.58% on 03/27/25
  • Expected Move (DTE 18) 2.81 (19.30%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 607
  • Volume Avg (30-Day) 1,385
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 39,315
  • Open Int (30-Day) 38,101
  • Expected Range 11.73 to 17.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 6
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.11
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.28 +41.34%
on 02/03/26
14.63 -0.65%
on 03/02/26
+3.92 (+36.95%)
since 02/02/26
3-Month
2.81 +417.08%
on 12/03/25
14.63 -0.65%
on 03/02/26
+11.64 (+402.77%)
since 12/02/25
52-Week
1.01 +1,338.61%
on 04/09/25
14.63 -0.65%
on 03/02/26
+13.16 (+960.58%)
since 02/28/25

Most Recent Stories

More News
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial...

ERAS : 14.53 (+6.37%)
Erasca to Present at Upcoming Conferences in February

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 14.53 (+6.37%)
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock?

Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash,...

ERAS : 14.53 (+6.37%)
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 14.53 (+6.37%)
Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 14.53 (+6.37%)
Erasca Announces Proposed Public Offering of $150 Million of Common Stock

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 14.53 (+6.37%)
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015...

ERAS : 14.53 (+6.37%)
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 14.53 (+6.37%)
Erasca to Present at the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 14.53 (+6.37%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 1.0200 (-9.73%)
IMRX : 5.00 (+0.20%)
ALXO : 2.12 (+0.47%)
ERAS : 14.53 (+6.37%)
PRLD : 2.71 (-1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 16.61
2nd Resistance Point 15.62
1st Resistance Point 15.07
Last Price 14.53
1st Support Level 13.54
2nd Support Level 12.55
3rd Support Level 12.00

See More

52-Week High 14.63
Last Price 14.53
Fibonacci 61.8% 9.42
Fibonacci 50% 7.82
Fibonacci 38.2% 6.21
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar